Results 261 to 270 of about 233,740 (307)
Impact of CD38 Deficiency on B Cell Development in CD19-Deficient Mice. [PDF]
Scand J ImmunolAbrego-Peredo A +6 more
europepmc +1 more source
Cancers, 2021 CAR-T cell therapy is not without some clinical adverse effects, namely cytokine storms, due to a massive release of cytokines when CAR-T cells multiply in the body.
Shabirul Haque
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Research in Translational Medicine
Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we report the results of a phase 2 study giving point of care produced CD19 CAR T- cells for r/r AML with aberrant expression of CD19 (NCT04257175).
Ivetta Danylesko +9 more
openaire +2 more sources
Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we report the results of a phase 2 study giving point of care produced CD19 CAR T- cells for r/r AML with aberrant expression of CD19 (NCT04257175).
Ivetta Danylesko +9 more
openaire +2 more sources
CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
2021ENGELS BORIS, GUIMARAES CARLA PATRICIA
openaire +4 more sources